Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy

• Co-developed novel technology platform combining S-layer proteins and emulsomes for diverse applications in bio-delivery of drugs and genes with the University of Natural Resources and Life Sciences (BOKU) Vienna
  

FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation drug delivery and cellular immunotherapy, together with Professor Uwe Sleytr and the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.

Avalon and Professor Uwe Sleytr of BOKU have jointly filed USPTO (US63/060,235) and international PCT (US21/38327) patent applications pertaining to the novel SLET platform.

As a vesicular nano-carrier system, emulsomes are composed of an internal lipoidal core surrounded by phospholipid multilayers. This emulsome nano-carrier, when loaded with bio-active agents (such as poorly water-soluble pharmaceuticals and genetic materials, including DNA and RNA), may increase their solubility and bioavailability. This nano-formulation is also designed to be safe and nontoxic. The SLET platform exploits the S-layer fusion proteins as coating materials for the emulsome nano-carriers, in order to provide a “molecular GPS system” to guide the trafficking and delivery of the emulsomal payload to a targeted destination in the body. Avalon is actively exploring the practical uses of SLET, including targeted drug delivery, vaccine development, diagnostic devices, and cellular therapeutic applications.

“We are very excited to announce this novel SLET platform, which we believe will help accelerate the development of our mRNA-based Flash-CAR™ program. The targeted delivery of mRNA to immune effector cells by SLET could open the door to a whole new generation of cancer immunotherapy. In addition, we see a number of other therapeutic and diagnostic applications for this broad and potentially transformative technology platform. Moreover, we believe these latest patent filings will provide us robust international IP protection for this technology and its many potential applications,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.

About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco

Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information: 
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com

Released October 14, 2021